Literature DB >> 8978303

Clinical and prognostic significance of femoral marrow magnetic resonance imaging in patients with malignant lymphoma.

S Tsunoda1, S Takagi, O Tanaka, Y Miura.   

Abstract

We evaluated 56 consecutive patients with newly diagnosed lymphoma including 48 with non-Hodgkin's lymphoma (NHL) and 8 with Hodgkin's disease to determine the clinical and prognostic significance of magnetic resonance imaging (MRI) of the femoral marrow. MR images of the femoral marrow were obtained by the T1-weighted spin echo method and the short TI inversion recovery technique. Abnormal "positive" images were seen in 29 of the 56 patients (52%). All 17 patients with positive biopsy results showed abnormal images on their femoral marrow MRI. Three "positive" MRI patterns-scattered (72%), uniform (21%), and nodular (7%)-were observed. The overall survival of the patients with a positive MRI pattern was significantly poorer than that of patients with a normal pattern (P = .0129). Survival did not differ significantly according to MRI pattern. The 3-year survival rate in the patients with a normal MRI pattern was 89.9% and in the patients with a positive MRI pattern, it was 41.0%. This difference was statistically significant (P = .0279) when we evaluated only the patients with NHL. Patients with positive MRI patterns, but a normal bone marrow histology, showed a significantly shorter survival than those with a normal MRI pattern (P = .016). These results indicate that abnormal MR images of the femoral marrow are associated with a significantly poorer survival in patients with malignant lymphoma, regardless of histologic findings in the marrow.

Entities:  

Mesh:

Year:  1997        PMID: 8978303

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Sarah J Vinnicombe; Rodney H Reznek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-23       Impact factor: 9.236

2.  Detection of bone marrow and extramedullary involvement in patients with non-Hodgkin's lymphoma by whole-body MRI: comparison with bone and 67Ga scintigraphies.

Authors:  Masami Iizuka-Mikami; Kiyohisa Nagai; Koji Yoshida; Takashi Sugihara; Yoshimasa Suetsugu; Makoto Mikami; Tsutomu Tamada; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Eur Radiol       Date:  2004-02-18       Impact factor: 5.315

3.  Clinical significance of magnetic resonance imaging of bone marrow in patients with leukemia.

Authors:  J Wang; X Zhang; J Niu
Journal:  J Tongji Med Univ       Date:  2001

4.  Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET.

Authors:  Hugo J A Adams; Thomas C Kwee; Malou A Vermoolen; Bart de Keizer; John M H de Klerk; Judit A Adam; Rob Fijnheer; Marie José Kersten; Jaap Stoker; Rutger A J Nievelstein
Journal:  Eur Radiol       Date:  2013-04-17       Impact factor: 5.315

5.  Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children.

Authors:  Christian J Kellenberger; Stephen F Miller; Mustafa Khan; David L Gilday; Sheila Weitzman; Paul S Babyn
Journal:  Eur Radiol       Date:  2004-09-09       Impact factor: 5.315

Review 6.  MR imaging of therapy-induced changes of bone marrow.

Authors:  Heike E Daldrup-Link; Tobias Henning; Thomas M Link
Journal:  Eur Radiol       Date:  2006-09-21       Impact factor: 5.315

7.  Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies.

Authors:  Ida Sofie Grønningsæter; Aymen Bushra Ahmed; Nils Vetti; Silje Johansen; Øystein Bruserud; Håkon Reikvam
Journal:  Clin Pract       Date:  2018-06-07

8.  Femoral marrow MRI is a non-invasive, non-irradiated and useful tool for detecting bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Shohei Ikeda; Saburo Tsunoda; Daisuke Koyama; Manabu Suzuki; Masumi Sukegawa; Kyohei Misawa; Hiroshi Hojo; Xin Zhu; Kenichi Utano; Masatsugu Ohta
Journal:  J Clin Exp Hematop       Date:  2021-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.